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BACKGROUND:  Isoferulic  acid  (IFA)  is  a  main  active
ingredient of the rhizoma of Cimicifuga heracleifolia,
which  is  used  frequently  in  Japanese  traditional
medicine as an anti-inflammatory drug. It has been
revealed that IFA  inhibits  the  production of macro-
phage  inflammatory  protein-2  (MIP-2),  which  is  a
murine  counterpart  of  the  chemokine  family  that
may contribute to the pathogenesis of inflammatory
diseases through the chemotactic activity for inflam-
matory and immune effector cells.
Aim of the study: In this study, we investigated the
therapeutic effect of IFA on the progression of lethal
influenza virus  pneumonia  in  mice  by  comparison
with that of dexamethasone (DX), a potent inhibitor
for various inflammatory cytokines including MIP-2.
Methods: Mice  were  infected  by  intranasal  inocula-
tion  of influenza virus  under ether anesthesia. The
IFA or DX was given by oral administration once daily
for 4 days after infection. After infection, the survival
rate  and  the  change  in  body  weight  were  daily
monitored.
Results: IFA  administration  markedly  improved  the
survival rate and body weight loss of influenza virus-
infected mice in a suitable dose range (0.5mg/day).
However,  DX  administration  did  not  show  a  bene-
ficial effect at any dose.
Conclusion: These data suggested that IFA is a novel
tool not only for the intervention therapy, but also for
the  studies  on  the  pathogenesis  of  influenza virus-
induced pneumonia.
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Introduction
Respiratory  infections  are  particularly  common  in
older  persons,  and  influenza  and  pneumonia  are
major causes  of  morbidity  and  mortality.1 We  have
previously  reported  that  macrophage  inflammatory
protein-2 (MIP-2), a murine counterpart of the chem-
okine family,2 plays a crucial role in the pathogenesis
of a lethal influenza virus pneumonia in mice, and the
administration  of  anti-MIP-2  antibody  improved  the
survival rate of the infected mice.3
The rhizoma of Cimicifuga spp., such as Cimici-
fuga heracleifolia Komarov and Cimicifuga dahur-
ica Maxim are used frequently as antipyretic, analge-
sic  and  anti-inflammatory  drugs  in  Japanese
traditional medicine. Especially, isoferulic acid (IFA),
3-(3-hydroxy-4-methoxyphenyl)-2-propenic  acid,  has
been recognized as the main active component of C.
heracleifolia extract  in  the  inflammation  model  in
rats.4 Furthermore, we previously reported that IFA
inhibited influenza virus-induced MIP-2 production in
vitro and in vivo.5 Considering the pathological role
of chemokine-induced neutrophil infiltration on vari-
ous animal inflammation models, IFA might exhibit a
beneficial effect on the lethal influenza virus pneumo-
nia in mice. In this study, we investigated whether IFA
administration improves the survival rate of influenza
infected mice by  comparing with administration of
dexamethasone (DX), which is a potent inhibitor of
MIP-2 production.5,6
Materials and methods
Preparation of drugs
IFA,  purchased  from  Carl  Roth  GmbH  (Karlsruhe,
Germany), was freshly prepared in serum-free phos-
phate-buffered  saline  (PBS)  at  a  concentration  of
5 mM. The dissolved drugs were sterilized by filtration
before use. DX, purchased from Sigma (St. Louis, MO,
USA), was also dissolved in PBS at a concentration of
2.0mg/ml and stored at –80°C until use.
Preparation of virus
The  lung-adapted  strain  of  influenza  A/PR/8/34
(PR8)  virus (H1N1 subtype) was propagated in the
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hen eggs for 48h at 35°C. The chorioallantoic fluid
was collected and stored in small portions at –80°C
after  centrifugation  at  1000  ´ g for  10min.  The
virus titer of the chorioallantoic fluid was 1.9 ´ 108
plaque  forming  units  (PFU)  as  determined on  Mar-
din–Darby  canine  kidney  cells,  as  described
previously.7
Virus infection of mice and administration of
drugs
An outbred specific pathogen free strain of ICR female
4-week-old mice (body weight, approximately 17g)
obtained from SLC Co. Ltd. (Hamamatsu, Japan) were
used for infection by intranasal inoculation of a virus
solution containing 4000 PFU/25 m l (four 50% lethal
doses of virus) under ether anesthesia. The IFA was
given by oral administration (0.5ml/mouse) at doses
of 0.25mg/day (group A), 0.5mg/day (group B) and
1.0mg/day (group C) once daily for 4 days on days 0
(just before infection), 1, 2 and 3 after infection. The
DX  was  administered  intraperitoneally  (0.5ml/
mouse) at doses of 4.0, 0.4 and 0.04mg/day by the
same manner as already described. As a control, mice
received 0.5ml PBS via oral or intraperitoneal admin-
istration  instead  of  IFA  or  DX,  respectively.  After
infection, the survival rate was daily monitored and
the change in body weight, a sensitive indicator of the
progression  of  viral  pneumonia  in  mice,  was  also
monitored.
Statistical analysis
The  data  of  survival  rate  and  body  weight  were
assessed  by  Fisher’s  exact  probability  test  and
unpaired t-test, respectively.
Results and discussion
In our previous report, the MIP-2 level in lung tissue
obtained from influenza infected mice had a peak on
day  2  and  then  sharply  decreased.3 Based  on  this
finding, IFA or DX was administered four times from
day 0 to day 3 after infection. As shown in Figure 1A,
the  untreated control mice  began  to  die  on  day  8
and  mortality rates successively increased until  day
10. The mice in group B (0.5mg/day IFA) also began
to die on day 8 but mortality rates increased gently
and, later than 10  days after infection, the survival
rates  of  group  B  were  significantly  improved  from
those of the control group. In group A (0.25mg/day
IFA),  a  beneficial  effect  on  the  survival  rates  (P =
0.016)  was slightly  observed on the limited period
after  infection  (days  10  and  11)  but,  in  group  C
(1.0mg/day IFA), no effect was observed throughout
the  experiment. These data indicate that IFA  has  a
window  (a  suitable  dose  range)  for  exhibiting  the
therapeutic  effect  for  this  infection  model.  The
beneficial  effect  of  IFA  administration  was  also
shown  in  body  weight  loss  (Fig.  1B).  The  body
weight loss of group B mice was significantly milder
than  that  of  the  control  group  on  day  4  and
thereafter. Although  there  was  no  statistical  differ-
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FIG. 1. (A) Effect of isoferulic acid (IFA) administration on the
survival rate of influenza virus-infected mice. The IFA was
given by oral administration at doses of 0.5mg/day (group A,
filled triangle), 1.0mg/day (group B, open circle) and 2.0mg/
day (group C, open triangle) once daily during the initial 4
days (0–3 days after infection). As a control (open square),
phosphate-buffered saline was given in the same manner.
The data from 20 to 21 mice in each group were assessed by
Fisher’s exact probability test. * Significant difference from
the  control  with  the  indicated  P value.  (B)  Effect  of  IFA
administration  on  body  weight  loss  of  influenza  virus-
infected mice. The changes in body weight of the infected
mice in each group shown in (A) were daily monitored and
expressed  as  the  mean  ±  SE  (error  bar)  using  the  same
symbols as (A). The data were assessed by unpaired t-test.
*Significant difference from the control with the indicated
P value.ence,  the body weight  of  mice  in  groups A  and  C
changed with a tendency of milder loss than that of
control.  In  this  connection,  it  has been  confirmed
that  IFA  administration  (1.0mg/day)  did  not  influ-
ence  the  body  weight  changes  of  uninfected  ICR
mice  during  the  experimental  period  (data  not
shown).
Because  it  is  well  known  that  DX  is  a  potent
inhibitor for the production of various inflammatory
cytokines including MIP-2, and also inhibits immuno-
logical reaction, i.e. antibody production,8,9 we fur-
ther studied the effect of DX on the influenza virus-
induced  pneumonia  in  mice.  However,  in  sharp
contrast to IFA, DX did not improve either the survival
rates or body weight loss at any doses (Fig. 2).
In summary, we have clearly demonstrated in this
study that IFA, but not DX, has a potential to exhibit
a  therapeutic  effect  on  the  progression  of  lethal
influenza  virus  pneumonia  in  mice.  It  has  been
shown  that  tissue-toxic  molecules  such  as  nitric
oxide and active oxygen radicals are involved in the
pathogenesis of influenza virus pneumonia in mice,
and  these  tissue-toxic  molecules  are  produced  by
neutrophils,  especially  chemokine-attracted  neutro-
phils.3,10–13 We  previously  reported  that  IFA  inhib-
ited  influenza  virus-induced  MIP-2  production  in
vitro and  in  vivo.5 These  findings  might  permit
speculation  that  IFA  exhibits  its  therapeutic  effect
via reduction  of  MIP-2  production,  and  thereby  by
reduction of neutrophil accumulation at the infected
sites. On the contrary, several studies have indicated
that  neutrophils  may  play  a  protective  role  by
limiting virus spread in the early phase of infection
and  phagocytized  influenza  virions.14,15 Thus,  the
window  effect  of  IFA  shown  in  this  study  might
reflect,  in  part,  that  the  progression  of  influenza
virus  pneumonia  in  mice  lay  on  the  balance  of
adverse  and  beneficial  roles  of  neutrophils. Taking
these facts together with our findings, it is evident
that IFA is not only a novel drug for the intervention
therapy,  but  also  an  attractive  drug  for  further
studies on the pathogenesis of influenza virus pneu-
monia in mice.
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